After a deadly clinical trial, will immune therapies for cancer be a bust?
By Damian Garde,
STAT
| 07. 08. 2016
Immune therapies have been hailed as the future of cancer treatments, with new drugs racking up excellent clinical results by turning the body’s natural defenses on tumors.
But Thursday’s news that three patients died in a trial of one such treatment has surprised oncologists and biotech investors, casting doubts on what looked like a blockbuster new approach to fighting cancer.
Here’s a rundown on the fatal trial and what it means for the rest of the field.
Continue reading on STAT
Image via Flickr/NIH Image Gallery
Related Articles
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Phil Galewitz, NPR | 01.20.2026
Serenity Cole enjoyed Christmas last month relaxing with her family near her St. Louis home, making crafts and visiting friends.
It was a contrast to how Cole, 18, spent part of the 2024 holiday season. She was in the hospital...
By Dan Barry and Sonia A. Rao, The New York Times | 01.26.2026
Photo by Gage Skidmore from Peoria, AZ, United States
of America, CC BY-SA 2.0, via Wikimedia Commons
Late last month, a woman posted a photograph on social media of a purple hat she had knitted, while a black-and-white dog...
.jpg){kind=link}